These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 648104)

  • 1. [The use of glucuronyl-glucosamino-glycan sulfate (3GS) in the treatment of cerebral and peripheral athero-arteriosclerotic pathology].
    Ciammaichella A; Solitro A; Torcia L; Arcuri P
    Clin Ter; 1978 Mar; 84(5):509-21. PubMed ID: 648104
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical research on the aged concerning the anti-sclerotic effect of a new heparinoid extract: glycuronoglucosaminoglycan sulfate (3GS)].
    Turpini R; Caliandro L; Cocchi A; Volpi F; Brusaioli G; Grignani G; Antognetti R
    Clin Ter; 1975 May; 73(3):213-36. PubMed ID: 123842
    [No Abstract]   [Full Text] [Related]  

  • 3. [Glucuronyl-glucosaminoglycan sulfate in therapy of atheroarteriosclerotic syndromes in geriatrics].
    Bompani R; Violi G
    Minerva Med; 1974 Nov; 65(83):4315-29. PubMed ID: 4279362
    [No Abstract]   [Full Text] [Related]  

  • 4. [Antithrombogenic action of a new extract: 3GS].
    Rusconi C; Orlando G
    Minerva Cardioangiol; 1975 Sep; 23(9):565-70. PubMed ID: 125860
    [No Abstract]   [Full Text] [Related]  

  • 5. [Rapid effect of glucuronyl glucosamine glycan sulfate on the blood levels of HDL-cholesterol in vascular diseases].
    Ferlito S; La Spina E; Cultrera E; Puleo F; Carrà G
    Arch Sci Med (Torino); 1982; 139(2):175-81. PubMed ID: 7138283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of glucuronyl-glucosamino-glycan sulfate in a group of patients with blood lipid disorders].
    Cossu G
    Clin Ter; 1979 Jan; 88(2):173-81. PubMed ID: 428197
    [No Abstract]   [Full Text] [Related]  

  • 7. [Sulodexide treatment approach in patients with atherosclerotic vascular disease with various localizations].
    Capone-Braga M; Tellini L; Boncompagni L; Bettoni M; Burali A; Bensi A
    Clin Ter; 1987 Jan; 120(1):25-31. PubMed ID: 2973852
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical experiences on the anti-dyslipidemic effect of a new sulfomucopolysaccharide of pancreatic origin].
    Castello S
    Clin Ter; 1971 Aug; 58(4):323-34. PubMed ID: 4258171
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapy of arteriosclerotic vasculopathies with arterial wall extract].
    Veccia F
    Clin Ter; 1967 Sep; 42(5):429-42. PubMed ID: 5617689
    [No Abstract]   [Full Text] [Related]  

  • 10. [Sulodexide in the therapy of vasculopathies].
    Postiglione F; Pisani P; Gisonni P; Perrotta P; Gisonni A; Canciello M; Napolitano L; Brighina G; Ragno I; Salzano A
    Clin Ter; 1986 May; 117(3):223-31. PubMed ID: 3524974
    [No Abstract]   [Full Text] [Related]  

  • 11. [Changes induced by D-thyroxine treatment in blood lipid indices in arteriosclerotic subjects].
    Notarbartolo A; Di Fede G; Cupidi G; Rini GB
    Boll Soc Ital Biol Sper; 1974 Aug; 50(13):979-83. PubMed ID: 4463989
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clearing and anti-platelet-aggregation effects of a heparinoid of natural origin].
    Marini U; Bastoni F; Gibelli A
    Clin Ter; 1974 Oct; 71(1):13-31. PubMed ID: 4138995
    [No Abstract]   [Full Text] [Related]  

  • 13. [Cinnarizine and phosphatidyl choline in the treatment of cerebral arteriosclerotic pathology and arteriosclerosis of the lower extremities. Comparative study].
    Ciammaichella A; Solitro A; Arcuri P
    Minerva Cardioangiol; 1975 Mar; 23(3):191-200. PubMed ID: 1128771
    [No Abstract]   [Full Text] [Related]  

  • 14. [Behavior of the thromboelastogram (TEG) in arteriosclerotic subjects treated with natural mucopolysaccharide substances].
    Garbagnati N; Iaschi P; Ciavarelli F; Carignola W
    Clin Ter; 1969 Jul; 50(2):125-31. PubMed ID: 4243098
    [No Abstract]   [Full Text] [Related]  

  • 15. [The clofibrate-dipyridamole combination in the prevention and therapy of arteriosclerotic vascular disease and its complications].
    Cucinotta D; Ferretti PG; Daccò L; Mazzera F
    G Clin Med; 1977; 58(11-12):475-86. PubMed ID: 608558
    [No Abstract]   [Full Text] [Related]  

  • 16. [Activity of glucuronyl-glucosamine-glycan sulfate in patients with dyslipemia. Medium-term study].
    Pedrazzi F; Bonazzi L; Peterlin F
    Clin Ter; 1975 May; 73(4):327-42. PubMed ID: 1240795
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of atherosclerosis with cobalt-containing preparations].
    Khodzhaev AKh; Ashirmatov AE; Mirochnik LM
    Klin Med (Mosk); 1972 Jan; 50(1):77-82. PubMed ID: 5020034
    [No Abstract]   [Full Text] [Related]  

  • 18. [Experience with polysponin therapy of atherosclerosis].
    Milimovka ME; Konovalov MN; Rybnikov NI; Dimant MI
    Vrach Delo; 1971 Jan; (1):63-5. PubMed ID: 5576585
    [No Abstract]   [Full Text] [Related]  

  • 19. [Comparative study of the fibrinolytic activity of dimethylbiguanide in prevention of thromboembolism in patients with angiocardiopathy].
    Molino N; Belluardo C
    Rass Int Clin Ter; 1968 Jun; 48(11):687-700. PubMed ID: 5738544
    [No Abstract]   [Full Text] [Related]  

  • 20. [Heparinoids in the treatment of dyslipemia in patients with diabetic vasculopathy: action of 3gs].
    Cavazzini MG
    Clin Ter; 1978 Jan; 84(1):41-64. PubMed ID: 75777
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.